epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-301, Phase III. Recruiting

Non-small cell lung cancer, second line

NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.

QTLs at a glance

Data to September 30th 2026. Each measure links to its chart below.

Ineligible patients randomised

2.9% against 5%

On course Within range

Missing primary endpoint data

2.5% against 15%

On course Within range

Lost to follow-up or withdrew consent

0.6% against 6%

On course Within range

Stopped study treatment early

2.3% against 15%

On course Within range

Will the result hold?

Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.

RankQTLLikelihoodImpactWhy it is likely hereWatched at sites byWarningLimitCritical
1Ineligible patients randomisedEvidence grade B22
  • Comorbidity exclusions (PD-15)From the design: Does the protocol exclude common comorbidities? Yes
  • Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? One or two
  • Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? One or two; Does the protocol exclude common comorbidities? Yes
  • Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? One or two
  • Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? One or two
4%5%14.5%
2Missing primary endpoint dataEvidence grade A13None of its drivers applies to this design10.1%15%33.2%
3Lost to follow-up or withdrew consentEvidence grade A13None of its drivers applies to this design4.5%6%24.3%
4Stopped study treatment earlyEvidence grade B12None of its drivers applies to this design12.5%15%22%

Ineligible patients randomised

Within range% of patients; benchmark median 3.2%

Show data
Ineligible patients randomised: running rate by month
MonthPatientsRate
Jul 202510%
Oct 2025120%
Jan 2026450%
Apr 2026802.5%
Jul 20261243.2%
Oct 20261712.9%

epiClinical assumption: above the 3.2% median; eligibility errors were reported in 39% of 82 trials

Missing primary endpoint data

Within range% of patients; benchmark median 7.9%

Show data
Missing primary endpoint data: running rate by month
MonthPatientsRate
Jan 202610%
Apr 2026128.3%
Jul 2026454.4%
Oct 2026802.5%

The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it

Lost to follow-up or withdrew consent

Within range% of patients; benchmark median 3.7%

Show data
Lost to follow-up or withdrew consent: running rate by month
MonthPatientsRate
Jul 202510%
Oct 2025120%
Jan 2026450%
Apr 2026800%
Jul 20261240%
Oct 20261710.6%

epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status

Stopped study treatment early

Within range% of patients; benchmark median 10.7%

Show data
Stopped study treatment early: running rate by month
MonthPatientsRate
Jul 202510%
Oct 2025120%
Jan 2026450%
Apr 2026800%
Jul 20261242.4%
Oct 20261712.3%

epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power

Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).

Breaches and decisions

No QTL in EPI-301 has passed its early-warning line, so nothing needs evaluating.

Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.